Open Access

Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial

Marcus Maurer, Iwona Kobielusz-gembala, E. Mitha, J. Leflein, M. Gotua, Bartlowmiej Kwiek, M. Metz, Michael Yellin, C. Taglienti, Rick Ma, Diego Alvarado, E. Paradise, J. Bernstein

2024.2.1JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

DOI: 10.1016/j.jaci.2023.11.873

Abstract

Abstract is not available.

Citation format

MAURER, Marcus, et al. Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: Top line results from a phase 2 trial. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024.